

NanoSphere Health Sciences Inc.

News Release

June 11, 2021 – Vancouver, BC. NanoSphere Health Sciences Inc. (CSE: NSHS) (“Nanosphere” or the “Company”) announces its intention to consolidate its currently issued and outstanding common shares on the basis of 20 pre-consolidation common shares for each 1 new post-consolidated common share.

On behalf of the Board of Directors

“Michael Iverson”

Michael Iverson, Chairman

For further information please contact:

Michael Iverson

Tel: 604-351-3351

Email: maiverson@telus.net

The Canadian Securities Exchange has neither reviewed or approved the contents of, nor accepts responsibility for the adequacy or accuracy of, this news release.

About NanoSphere

NanoSphere Health Sciences is a nanobiotechnology firm specializing in proprietary delivery systems for therapeutic agents. Our patented technology transforms our strategic partner’s *good products into great products*, further differentiating them in their respective markets.

For more information on NanoSphere, please visit: www.NanoSphereHealth.com.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions, none of which can be assured, and are subject to risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Without limitation, these include assumptions, risks and uncertainties inherent in completing sub-licensing arrangements in the United States, Canada and abroad, product demand, production, competition and government regulation of the Cannabis industry, any and all of which may have an adverse effect on the Company’s expansion plans, sales, revenues and its financial results and condition. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.